By Dr. John L. Ferrell III, M.D.(*)
⚡ Quick Answer
PRP (platelet-rich plasma) is derived from a standard blood draw and delivers a concentrated dose of growth factors to the injured area. BMAC (bone marrow aspirate concentrate) is derived from a bone marrow harvest and delivers a broader mix of healing components, including mesenchymal stem cells. For mild to moderate tendon injuries and early joint degeneration, PRP is typically the right starting point: it is less invasive, less expensive, and has strong evidence for the most common presentations. BMAC is generally reserved for more advanced joint damage, larger structural injuries, or cases where PRP has produced insufficient results. Some patients benefit from both treatments used together. The right answer depends on what your imaging shows, not on which treatment sounds more advanced.
Patients who have researched regenerative medicine often arrive at the same question: if BMAC includes stem cells and PRP does not, isn’t BMAC always better? It seems logical. More components, more regenerative power, better outcomes.
The reality is more nuanced. PRP and BMAC are not ranked treatments where one is superior and the other is inferior. They are different tools with different mechanisms, different cost profiles, and different indications. Choosing between them is a clinical decision, not a consumer upgrade.
How Each Treatment Works
PRP starts with a standard blood draw from the arm, typically 30 to 60 mL. The blood is processed in a centrifuge to separate and concentrate the platelet fraction. Platelets are rich in growth factors, including PDGF (platelet-derived growth factor), TGF-beta (transforming growth factor), and VEGF (vascular endothelial growth factor), which signal the body’s repair cascade, modulate inflammation, and stimulate cell activity in damaged tissue. The resulting concentrate is injected directly into the injured area under ultrasound guidance.
The entire process takes about 45 minutes from blood draw to injection. There is no surgical step, no significant downtime, and no harvest site to recover from.
BMAC begins with a bone marrow aspiration, typically from the posterior iliac crest of the pelvis. Under local anesthesia, a needle is introduced into the bone marrow cavity and a sample of marrow is withdrawn. This sample is then centrifuged to concentrate the cellular components. The resulting BMAC product contains mesenchymal stem cells (MSCs), hematopoietic progenitor cells, platelets, and growth factors, generally at higher concentrations than those found in PRP.
The MSCs in BMAC are the key distinction. Unlike platelets, MSCs have the capacity to differentiate into multiple cell types, including bone, cartilage, and tendon cells, and to modulate the local immune environment in ways that pure platelet concentrates cannot. Comparative research on cellular and growth factor composition (Cavallo et al., PMC5845506) has found BMAC trending higher in PDGF, TGF-beta, and VEGF than standard PRP preparations, though the growth factor differences are not always statistically significant. Where BMAC clearly separates from PRP is the cellular components, the MSCs and progenitor cells, that PRP does not contain at all.
BMAC preparation and injection takes longer than PRP, involves a more invasive harvest step, and requires a brief recovery from the aspiration site. It is also meaningfully more expensive.
What the Research Shows
For knee osteoarthritis specifically, head-to-head studies have compared BMAC and PRP directly.
A one-year, non-randomized comparative study published in BMC Musculoskeletal Disorders (El-Kadiry et al., PMC8623697) followed 26 BMAC-treated knees and 13 PRP-treated knees. At 12 months, the BMAC group showed statistically significant improvement in VAS pain, KOOS, and WOMAC scores (mean improvements of 57.4%, 75.9%, and 74.0% respectively), while the PRP group’s improvement did not reach statistical significance over the same period. BMAC outperformed PRP by a wide margin on every measure tracked.
For patients with more advanced joint degeneration, a separate 4-year follow-up study of 37 knees with severe (Kellgren-Lawrence grade III to IV) osteoarthritis reported a 95% success rate and significant improvement in walking distance with BMAC alone. That study did not include a PRP comparison group and involved a relatively small patient sample, so the 95% figure describes BMAC’s own durability in severe OA over time, not a head-to-head advantage over PRP. It is a meaningful data point on BMAC’s staying power, not a claim that BMAC beats PRP by that margin.
Taken together, the current evidence supports BMAC as the stronger performer in comparative knee OA trials, particularly for patients who need more than a temporary symptom improvement. What the evidence does not clearly establish is a specific advantage for BMAC in milder OA grades over PRP. Severity remains one factor among several, alongside the patient’s goals, prior treatment history, cost tolerance, and the specific tissue involved.
When PRP Is the Right First Choice
PRP remains the appropriate starting point for most patients considering regenerative treatment. It is well-supported by evidence, less invasive, less expensive, and effective for a broad range of conditions when the injury is mild to moderate.
Conditions where PRP is typically recommended first: mild to moderate knee osteoarthritis (Kellgren-Lawrence grades 1 to 2) when the patient has not yet tried regenerative treatment; tendinopathies including lateral epicondylitis, patellar tendinopathy, Achilles tendinopathy, and rotator cuff tendinopathy; soft tissue injuries including partial ligament tears, muscle strains, and plantar fasciitis; patients who want to begin with the least invasive option and escalate if needed.
PRP’s advantage in these cases is not just clinical. The procedure is faster, the cost is lower, the recovery from the injection is minimal, and for many of these conditions the evidence for PRP is as strong as for BMAC. Starting with PRP and reassessing at three to six months is a clinically sound approach.
When BMAC Is the Better Option
BMAC becomes the more appropriate choice when the clinical picture outpaces what platelets alone can address.
BMAC is typically recommended when: the patient has moderate to severe knee or hip osteoarthritis with significant cartilage compromise; there is a larger structural injury such as a significant partial tendon tear or complex joint pathology; PRP has been attempted and produced insufficient improvement; the patient’s goals require the maximum available regenerative response and cost is not the primary constraint; or when the treating physician’s imaging-based assessment indicates that the MSC component of BMAC will provide a meaningful advantage over platelet growth factors alone.
It is worth being direct about cost. BMAC is meaningfully more expensive than PRP. Most insurance plans currently classify BMAC as investigational, meaning it is typically paid for out of pocket, though HSA and FSA funds can generally be used toward it. The exact cost depends on the joint involved and whether it is combined with other treatments. If cost is a deciding factor for you, ask about specific pricing at your evaluation.
Can PRP and BMAC Be Combined?
Some regenerative medicine practices combine PRP and BMAC in the same treatment session. The rationale is that PRP can serve as a biologically active scaffold that supports the MSCs delivered by BMAC, with the growth factor-rich platelet concentrate creating a more favorable local environment for stem cell activity.
Whether combination therapy is appropriate for a specific patient depends on the diagnosis, the imaging findings, and the clinical judgment of the treating physician. It is not the default protocol for most cases, but it is a legitimate option worth discussing at your evaluation if your case involves more advanced joint damage.
Frequently Asked Questions
Q: Which is better for knee arthritis, BMAC or PRP?
A: For early knee osteoarthritis, PRP is typically the appropriate starting treatment based on its evidence base and lower cost. For moderate to severe osteoarthritis, BMAC has shown stronger outcomes in head-to-head comparative studies, with statistically significant improvement over PRP at 12 months in at least one direct comparison. Your physician’s recommendation should be based on what the imaging shows, not on a blanket preference for either treatment.
Q: How much does BMAC cost compared to PRP?
A: BMAC involves a more invasive harvest step and a more resource-intensive lab process than PRP, and it costs meaningfully more as a result. Most insurance plans classify BMAC as investigational and do not cover it, though HSA and FSA funds can typically be applied. Because pricing varies by joint and treatment plan, the most accurate number for your situation comes from your evaluation, not a general industry figure.
Q: Is BMAC the same as stem cell therapy?
A: BMAC contains mesenchymal stem cells (MSCs), so it is technically a form of autologous stem cell therapy. However, the term “stem cell therapy” is used loosely in the market and is sometimes applied to treatments that do not actually contain live stem cells. BMAC derived from your own bone marrow is a legitimate source of MSCs. Treatments marketed as “stem cell” that use amniotic fluid, umbilical cord tissue, or placental products are different in composition and regulatory status. When in doubt, ask your provider exactly what the product contains and where it comes from.
Q: Does BMAC hurt more than PRP?
A: The BMAC procedure involves an additional step, the bone marrow aspiration from the pelvis, that PRP does not. That step is performed under local anesthesia and is generally well-tolerated, but patients may experience soreness at the harvest site for a few days after the procedure. The actual injection into the joint or tendon is similar for both treatments.
Q: How do I know which treatment is right for me?
A: The right starting point is a diagnostic evaluation with musculoskeletal ultrasound imaging, which gives your physician a real-time picture of the tissue before recommending treatment. At ROSM, that evaluation happens at your first visit. Treatment recommendations follow from what the imaging shows, your prior treatment history, your goals, and your cost considerations, not from a default preference for one treatment over another.
Conclusion
BMAC and PRP are both legitimate regenerative options with good clinical evidence. The decision between them is not about which sounds more advanced. It is about matching the treatment to the diagnosis.
For most patients, PRP is the right place to start. For patients with more advanced joint damage, or those who have had an inadequate response to PRP, BMAC offers a more powerful regenerative tool backed by stronger head-to-head outcomes data. For some patients, the combination of both is the most appropriate approach.
If you are trying to decide which treatment is appropriate for your situation, the answer starts with imaging, not assumptions. Schedule an evaluation at ROSM and let the diagnostic picture drive the recommendation.
Schedule Your Evaluation | Learn About BMAC at ROSM | Learn About PRP at ROSM
